Raras
Buscar doenças, sintomas, genes...
Psoríase pustular generalizada
ORPHA:247353CID-10 · L40.1CID-11 · EA90.40DOENÇA RARA

É uma forma rara e grave de psoríase, marcada pelo aparecimento de bolinhas de pus (chamadas pústulas) que são estéreis (ou seja, não têm bactérias) e podem surgir de muitas maneiras diferentes no corpo. Todas as principais características da doença (o que ela causa no corpo) se manifestam de forma muito mais intensa. A psoríase pustulosa generalizada é muito diversa na forma como se apresenta: ela pode começar em idades diferentes, ser causada por fatores variados, ter diferentes níveis de gravidade e evoluir de maneiras distintas ao longo da vida. Existem várias formas da doença que se parecem ou se misturam. Existe uma relação entre essas formas e a psoríase em placas (um tipo comum de psoríase), já que algumas pessoas podem apresentar crises de psoríase em placas antes ou depois dos episódios de psoríase pustulosa generalizada. Em outros casos, porém, a psoríase pustulosa generalizada é a única manifestação que a pessoa tem, sem que nunca apareça a psoríase em placas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma forma rara e grave de psoríase, marcada pelo aparecimento de bolinhas de pus (chamadas pústulas) que são estéreis (ou seja, não têm bactérias) e podem surgir de muitas maneiras diferentes no corpo. Todas as principais características da doença (o que ela causa no corpo) se manifestam de forma muito mais intensa. A psoríase pustulosa generalizada é muito diversa na forma como se apresenta: ela pode começar em idades diferentes, ser causada por fatores variados, ter diferentes níveis de gravidade e evoluir de maneiras distintas ao longo da vida. Existem várias formas da doença que se parecem ou se misturam. Existe uma relação entre essas formas e a psoríase em placas (um tipo comum de psoríase), já que algumas pessoas podem apresentar crises de psoríase em placas antes ou depois dos episódios de psoríase pustulosa generalizada. Em outros casos, porém, a psoríase pustulosa generalizada é a única manifestação que a pessoa tem, sem que nunca apareça a psoríase em placas.

Pesquisas ativas
12 ensaios
61 total registrados no ClinicalTrials.gov
Publicações científicas
1.163 artigos
Último publicado: 2026 Mar

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.18
France
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: L40.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
2 sintomas
📏
Crescimento
2 sintomas
🫃
Digestivo
1 sintomas
❤️
Coração
1 sintomas
🫘
Rins
1 sintomas
🧬
Pele e cabelo
1 sintomas

+ 19 sintomas em outras categorias

Características mais comuns

100%prev.
Placa eritematosa
100%prev.
Artralgia
100%prev.
Taxa de sedimentação de eritrócitos elevada
100%prev.
Pústula
90%prev.
Eritrodermia
Muito frequente (99-80%)
90%prev.
Dor
Muito frequente (99-80%)
27sintomas
Muito frequente (7)
Frequente (8)
Ocasional (9)
Muito raro (3)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 27 características clínicas mais associadas, ordenadas por frequência.

Placa eritematosaErythematous plaque
Muito frequente100%
ArtralgiaArthralgia
Muito frequente100%
Taxa de sedimentação de eritrócitos elevadaElevated erythrocyte sedimentation rate
Muito frequente100%
PústulaPustule
Muito frequente100%
EritrodermiaErythroderma
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.163PubMed
Últimos 10 anos200publicações
Pico2025140 papers
Linha do tempo
2026Hoje · 2026🧪 2006Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive, Not applicable.

AP1S3AP-1 complex subunit sigma-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. Involved in TLR3 trafficking (PubMed:24791904)

LOCALIZAÇÃO

Golgi apparatusCytoplasmic vesicle membraneMembrane, clathrin-coated pit

VIAS BIOLÓGICAS (2)
MHC class II antigen presentationLysosome Vesicle Biogenesis
MECANISMO DE DOENÇA

Psoriasis 15, pustular

A form of pustular psoriasis, a life-threatening disease defined by repeated flares of sudden onset consisting of diffuse erythematous skin eruption characterized by rapid coverage with pustules, high-grade fever, asthenia, marked leukocytosis, and elevated serum levels of C-reactive protein.

OUTRAS DOENÇAS (4)
psoriasis 14, pustularpustulosis palmaris et plantarisgeneralized pustular psoriasispsoriasis 15, pustular, susceptibility to
HGNC:18971UniProt:Q96PC3
IL36RNInterleukin-36 receptor antagonist proteinDisease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus

LOCALIZAÇÃO

CytoplasmSecreted

VIAS BIOLÓGICAS (1)
Interleukin-36 pathway
MECANISMO DE DOENÇA

Psoriasis 14, pustular

A life-threatening disease defined by repeated flares of sudden onset consisting of diffuse erythematous skin eruption characterized by rapid coverage with pustules, high-grade fever, asthenia, marked leukocytosis, and elevated serum levels of C-reactive protein.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Sun Exposed Lower leg
82.0 TPM
Skin Not Sun Exposed Suprapubic
49.1 TPM
Esôfago - Mucosa
21.0 TPM
Vagina
3.8 TPM
Testículo
0.2 TPM
OUTRAS DOENÇAS (3)
psoriasis 14, pustulargeneralized pustular psoriasispustulosis palmaris et plantaris
HGNC:15561UniProt:Q9UBH0

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 SPEVIGO (SPESOLIMAB-SBZO)
💊 SPEVIGO (SPESOLIMAB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

67 variantes patogênicas registradas no ClinVar.

🧬 IL36RN: NM_012275.3(IL36RN):c.41C>A (p.Ser14Ter) ()
🧬 IL36RN: NM_012275.3(IL36RN):c.205_212del (p.Ser69fs) ()
🧬 IL36RN: NM_012275.3(IL36RN):c.273del (p.Ala92fs) ()
🧬 IL36RN: NM_012275.3(IL36RN):c.16del (p.Ala6fs) ()
🧬 IL36RN: GRCh37/hg19 2q12.2-21.2(chr2:106755586-134302739)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 188 variantes classificadas pelo ClinVar.

28
19
141
Patogênica (14.9%)
VUS (10.1%)
Benigna (75.0%)
VARIANTES MAIS SIGNIFICATIVAS
IL36RN: NM_012275.3(IL36RN):c.41C>A (p.Ser14Ter) [Pathogenic]
IL36RN: NM_012275.3(IL36RN):c.273del (p.Ala92fs) [Pathogenic]
IL36RN: NM_012275.3(IL36RN):c.16del (p.Ala6fs) [Pathogenic]
IL36RN: NM_012275.3(IL36RN):c.244-9T>A [Uncertain significance]
IL36RN: NM_012275.3(IL36RN):c.164C>G (p.Ser55Cys) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 36
2Fase 25
1Fase 11
·Pré-clínico7
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Psoríase pustular generalizada

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

61 ensaios clínicos encontrados, 12 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
812 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 812

#1

[Role and clinical significance of PD-L1+ neutrophils in generalized pustular psoriasis].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology2026 Feb

Objective To characterize the distribution and functional phenotype of programmed death-ligand 1 (PD-L1) positive neutrophils in generalized pustular psoriasis (GPP) and determine their associations with disease severity and treatment response. Methods We integrated bioinformatic analyses with clinical samples to compare PD-L1 expression on neutrophils from peripheral blood and lesional skin among patients with GPP, healthy controls (HC), and psoriasis vulgaris (PV). PD-L1+ neutrophils were magnetically isolated from HC peripheral blood for in vitro culture, and 24 hours apoptosis was assessed by flow cytometry. The proportion of PD-L1+ neutrophils was quantified by flow cytometry and immunofluorescence and correlated with clinical indices -including GPPASI, high-sensitivity C-reactive protein (hsCRP), neutrophil-to-lymphocyte ratio (NLR), and relapse frequency, as well as clinical response to spesolimab. Results PD-L1 expression on neutrophils was significantly upregulated in both peripheral blood and lesional skin of patients with GPP, showing marked differences compared with HC and PV patients. PD-L1+ neutrophils exhibited delayed apoptosis at 24 hours and a pro-inflammatory phenotype characterized by increased release of IL-36γ-processing enzymes. PD-L1 levels correlated positively with GPPASI, hsCRP, and NLR. The proportion of lesional PD-L1+CD15+ neutrophils was positively associated with relapse frequency. Patients with higher baseline PD-L1 levels demonstrated better clinical responses to spesolimab. Conclusion PD-L1+ neutrophils are enriched in GPP and display delayed apoptosis and inflammatory activation. Their abundance is closely linked to disease activity, systemic inflammation, and biologic response, suggesting a role in shaping GPP immune heterogeneity. PD-L1+ neutrophils are merit consideration as a practical immunologic biomarker for monitoring disease activity and guiding individualized biologic therapy.

#2

Disease Modification of Pustular Psoriasis by Secukinumab: A 20-Year Follow-Up of Von Zumbusch-Type Generalized Pustular Psoriasis With Evolution Into Annular Pustular Psoriasis-A Case Report.

The Kaohsiung journal of medical sciences2026 Jan
#3

Repeated Episodes of GPP Induced by Respiratory Infections Are Mediated by Loss-of-Function IFIH1.

Immunity, inflammation and disease2026 Mar

Generalized pustular psoriasis (GPP) is a severe and recurrent autoinflammatory disease that can be induced by a variety of factors. At present, its etiology and pathogenesis have not yet been fully elucidated. Upper respiratory tract infections are the main predisposing factor in children with GPP, and the MDA5 protein encoded by the IFIH1, functions as a key receptor for sensing upper respiratory tract viruses and may contribute to the induction of antiviral and immunological responses. We performed whole-exome sequencing in 80 pediatric GPP patients and conducted rare variant association analyses against healthy controls. Structural and expression analyses of mutant MDA5 were performed to evaluate mechanistic consequences. Identified IFIH1 variants were functionally characterized using IFN-β luciferase reporter assays, circular dichroism spectroscopy, and protein stability assays. We identified eight IFIH1 rare variants in 10 pediatric GPP patients, accounting for 12.5% of the total cohort. Association analyses revealed a significantly higher prevalence of rare variants of IFIH1 in GPP patients as compared to healthy controls. IFIH1 variation was found to cause structural changes or decreased expression of its encoded protein MDA5, the intrinsic stability of the mutant was lower than that of the wild-type IFIH1. Notably, functional assays demonstrated that these IFIH1 variants (6/8) substantially impaired the production of interferon beta (IFN-β). This study suggests that loss-of-function variants in IFIH1 may be associated with the pathogenesis of recurrent episodes of GPP triggered by URTI. These findings offer a theoretical basis for the development of targeted etiological and pathogenetic preventive measures.

#4

Complications and Laboratory Test Findings Among Patients With Generalized Pustular Psoriasis: A Retrospective Chart Review Study.

Experimental dermatology2026 Mar

Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterised by widespread eruption of sterile, macroscopic pustules. Patients with GPP can present with multiple comorbidities that may influence treatment. This study aimed to assess the frequency of psoriasis-related complications and non-psoriasis-related comorbidities, and clinical laboratory findings, at the time of GPP diagnosis among patients with GPP. This was a retrospective, longitudinal medical chart review of data from patients with a documented GPP diagnosis attending 29 GPP referral hospitals in Japan. Demographics and clinical characteristics were assessed at baseline (within 6 months prior to and 3 months after GPP diagnosis), including psoriasis-related complications, non-psoriasis-related comorbidities, and clinical laboratory findings. Overall, 205 patients with GPP were included; 48.3% were female, and median age at initial diagnosis was 53 years. Similar proportions of patients had mild (36.1%), moderate (30.7%) and severe (33.2%) GPP at baseline, using Japanese Dermatological Association-GPP severity criteria. Most patients (69.8%) had psoriasis-related complications at baseline, with the most common being psoriasis vulgaris (42.9%) and psoriatic arthritis (26.8%). Non-psoriasis-related comorbidities were present in 69.3% of patients with GPP at baseline, with the most common being hypertension (28.3%), dyslipidaemia (16.6%) and diabetes mellitus (16.1%). There was large variability in laboratory test values between patients. These results demonstrated that, at the time of GPP diagnosis, patients with GPP have multiple burdens of both psoriasis-related complications and non-psoriasis-related comorbidities.

#5

Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies.

Cureus2026 Feb

Generalized pustular psoriasis (GPP) is a rare, life-threatening auto-inflammatory disease driven by IL-36 pathway dysregulation leading to recurrent flares of widespread erythema, sterile pustules, and systemic symptoms. Real-world data on spesolimab - the first U.S. Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved GPP therapy - remains scarce, particularly outside Europe. We performed a retrospective case series with prospective follow-up (2010-2025) following Consensus-based Clinical Case Reporting (CARE) guidelines. Nine patients diagnosed according to European Rare and Severe Psoriasis Expert Network (ERASPEN) criteria by board-certified dermatologists were included. Data on demographics, triggers, clinical features, complications, and treatments were collected from electronic medical records. Nine patients (100%) aged 3-61 years, including five (55.6%) female patients, were included. Obesity was the most common comorbidity (n=6, 66.7%). Steroid withdrawal was the most common trigger (n=5, 55.6%). All patients presented with generalized erythema, sterile pustules, and pain; complications observed were acute respiratory distress syndrome (ARDS) in two patients (22.2%) and acute cholangitis in one patient (11.1%). Six flares required inpatient care. Spesolimab achieved 100% flare-free status at 12 months versus 50-75% recurrence with non-IL-36 agents. A tiered treatment algorithm was proposed, prioritizing rapid IL-36 blockade in severe flares. This largest Latin American GPP cohort reveals an earlier onset in pediatric patients and high complication rates. Spesolimab shows superior flare control, but access barriers persist. Standardized protocols and genetic studies in diverse populations are urgently needed.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC846 artigos no totalmostrando 198

2026

Novel Heterozygous Hypomorphic MPO Variant Identified in Impetigo Herpetiformis.

The Journal of dermatology
2026

Repeated Episodes of GPP Induced by Respiratory Infections Are Mediated by Loss-of-Function IFIH1.

Immunity, inflammation and disease
2026

Successful Discontinuation of Systemic Corticosteroids With Secukinumab in a Pediatric Case of Generalized Pustular Psoriasis Harboring an IL36RN Mutation.

The Journal of dermatology
2026

Complications and Laboratory Test Findings Among Patients With Generalized Pustular Psoriasis: A Retrospective Chart Review Study.

Experimental dermatology
2026

Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies.

Cureus
2026

De novo Generalized Pustular Psoriasis: A Tofacitinib-Induced Paradoxical Adverse Event.

Indian dermatology online journal
2026

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy
2026

Annular generalized pustular psoriasis successfully managed with spesolimab induction and secukinumab maintenance.

Medicina clinica
2026

The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum.

Medicina (Kaunas, Lithuania)
2026

Targeting the IL-36 Pathway: Spesolimab as a Therapeutic for Acute Flares of Pustular Psoriasis.

Cureus
2026

The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases.

Allergology international : official journal of the Japanese Society of Allergology
2026

Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland.

Acta dermato-venereologica
2026

Severe Generalized Pustular Psoriasis With Systemic Capillary Leak Syndrome Successfully Treated With Spesolimab: A Case Report.

The Journal of dermatology
2026

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Journal of drugs in dermatology : JDD
2025

Dupilumab-induced generalized pustular psoriasis in a Chinese woman with atopic dermatitis.

Postepy dermatologii i alergologii
2025

The efficacy and safety of spesolimab in patients with generalized pustular psoriasis flares: a systematic review and meta-analysis.

Frontiers in medicine
2026

[Role and clinical significance of PD-L1+ neutrophils in generalized pustular psoriasis].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
2026

Interleukin-36 receptor antagonist deficiency patient with a novel mutation.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2026

Generalized pustular psoriasis induced by an intraductal pancreatic tumour producing IL-36γ: A case report.

Journal of the European Academy of Dermatology and Venereology : JEADV
2026

Sustained efficacy of spesolimab following flare-up dose in achieving long-term skin clearance in generalized pustular psoriasis: A case report and review of literature.

JAAD case reports
2025

Severe, Resistant Generalized Pustular Psoriasis-Associated Inflammatory Syndrome Successfully Treated With Adalimumab: A Case Report.

Cureus
2026

[Generalized pustulosis after leflunomide].

Dermatologie (Heidelberg, Germany)
2026

Treatment of Generalized Pustular Psoriasis with Abrocitinib: A Case Report.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2026

Acute Myocarditis During a Generalized Pustular Psoriasis Flare: A Possible Pharmacogenetic Interaction in the Setting of Severe Systemic Inflammation?

The Journal of dermatology
2026

Real-World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP).

The Journal of dermatology
2026

Acute methotrexate-induced cutaneous ulceration in generalized pustular psoriasis: A case report and review of the literature.

JAAD case reports
2025

Clinical differentiation between acute generalized exanthematous pustulosis and generalized pustular psoriasis: A multi-center study.

Chinese medical journal
2026

Serum neutrophil gelatinase-associated lipocalin as a potential signature for acute generalized exanthematous pustulosis and generalized pustular psoriasis: A case-control study.

JAAD international
2025

Dynamic neutrophil-keratinocyte communication network centered on IL-36/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis.

Nature communications
2025

Clinical phenotype of 504 pustular psoriasis patients from Europe and Egypt: a multi-center observational study.

Clinical and experimental dermatology
2025

Distinct Mortality Risks in Generalized Pustular Psoriasis and Palmoplantar Pustulosis: A Nationwide, Population-Based, Cohort Study.

Dermatology (Basel, Switzerland)
2025

Spesolimab Rapidly Resolved Capillary Leak Syndrome Associated with Generalized Pustular Psoriasis.

Acta dermato-venereologica
2025

Generalized Pustular Psoriasis Confers Increased Risk of Pyoderma Gangrenosum: First Population-Based Evidence.

Dermatology (Basel, Switzerland)
2026

Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

Actas dermo-sifiliograficas
2025

Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study.

Journal of psoriasis and psoriatic arthritis
2025

Successful treatment with secukinumab in a 4-month-old infant with severe generalized pustular psoriasis: a case report.

Frontiers in medicine
2025

Sequential Treatment of Generalized Pustular Psoriasis Combined with Bullous Pemphigoid Using Spesolimab and Dupilumab: A Case Report and Literature Review.

Case reports in dermatology
2025

Epidemiology, clinical characteristics, flares and mortality of generalized pustular psoriasis: a nationwide register study in Finland.

Skin health and disease
2025

Rare coexistence of generalized pustular psoriasis and discoid lupus erythematosus with worsening of lupus lesions after bimekizumab therapy: a case report.

European journal of dermatology : EJD
2025

Cross-spectrum efficacy of spesolimab in IL-36-mediated dermatoses: a 'case study.

The Journal of dermatological treatment
2025

Safety of secukinumab in pregnant patients with pustular psoriasis: a case report on two successful pregnancies and their offspring outcomes.

The Journal of dermatological treatment
2026

Clinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis.

Dermatology (Basel, Switzerland)
2025

Temporal trends and real-world effectiveness of biologic therapies in generalized pustular psoriasis: a 7-year retrospective cohort study.

The Journal of dermatological treatment
2025

Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment.

Clinical and experimental medicine
2026

Biologic therapy for generalized pustular psoriasis: Real-world comparative effectiveness in a single-center.

Journal of the American Academy of Dermatology
2026

Amoxicillin-Triggered Flare of Generalized Pustular Psoriasis in a Patient With Homozygous IL36RN Pathogenic Variant Treated With Spesolimab and Cyclosporin A.

The Journal of dermatology
2026

Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction-Associated Steatotic Liver Disease.

The Journal of dermatology
2026

Successful Treatment of Post-Transplant Generalized Pustular Psoriasis With Apremilast.

The Journal of dermatology
2025

A prospective, observational study on the epidemiology, disease characteristics and treatment outcomes for generalized pustular psoriasis in India.

Clinical and experimental dermatology
2025

Co-Occurrence of RAD21 and TNFAIP3 Mutations in Cornelia de Lange Syndrome with Pustular Psoriasis: Potential Molecular Interactions.

International journal of molecular sciences
2025

Highlights of the Brazilian Society of Dermatology's Brazilian Consensus on Psoriasis.

Anais brasileiros de dermatologia
2026

Dual impact of smoking cessation and post-cessation weight change on psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV
2026

Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis.

Dermatology and therapy
2025

[Generalized pustular psoriasis: a rare entity in pediatrics].

Boletin medico del Hospital Infantil de Mexico
2025

Clinical characteristics, treatment outcomes, and relapse prediction in 199 patients with generalized pustular psoriasis: a retrospective cohort study.

The Journal of dermatological treatment
2025

Case Report: Hydroxychloroquine-induced generalized pustular psoriasis in a pediatric patient with systemic lupus erythematosus.

Frontiers in pediatrics
2025

Utility and Limitations of Large Language Models to Simplify Online Content on Generalized Pustular Psoriasis.

Rhode Island medical journal (2013)
2025

Efficacy and Safety of Tumor Necrosis Factor Alpha Inhibitors for Generalized Pustular Psoriasis of Pregnancy: A Review of Reported Cases.

Journal of cutaneous medicine and surgery
2025

Spesolimab for acute-flare generalized pustular psoriasis with severe erythema and plaques: A case report.

Medicine
2025

The roles of serine protease inhibitors in dermatoses.

Frontiers in genetics
2026

Biologic therapies for dermatologic emergencies: A comprehensive review.

Journal of the American Academy of Dermatology
2026

Generalized pustular psoriasis treated with additional biologics after spesolimab: a case series from Japan.

Clinical and experimental dermatology
2025

Clinical Features, Treatment Effectiveness and Long-Term Outcomes in Children with Moderate-to-Severe Generalized Pustular Psoriasis: A Retrospective Cohort Study.

Journal of inflammation research
2025

Hypocalcemia-related pustulosis: a case report.

Journal of medical case reports
2025

Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review.

Dermatology and therapy
2025

Generalized pustular psoriasis in Caucasian patient successfully and rapidly treated with bimekizumab.

Italian journal of dermatology and venereology
2025

Early Real-Life Experience with Spesolimab in the Treatment of Generalized Pustular Psoriasis: A Case Series of Three Patients Treated in a Compassionate Use Program.

Case reports in dermatology
2025

Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity.

The Journal of dermatological treatment
2025

Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children.

Pediatric dermatology
2026

Refractory Pediatric Generalized Pustular Psoriasis Successfully Treated With Spesolimab.

International journal of dermatology
2025

Generalized pustular psoriasis with purpura and haemorrhagic blisters.

European journal of dermatology : EJD
2025

Secukinumab-induced erythema multiforme-like drug eruption in generalized pustular psoriasis: a case report and literature review.

European journal of dermatology : EJD
2025

Combination therapy with spesolimab and apremilast for refractory generalized pustular psoriasis: a case report.

Frontiers in medicine
2025

Spesolimab for patients with generalized pustular psoriasis flares: Real-world experience in China.

Chinese medical journal
2025

Generalized pustular psoriasis: Advances in pathogenesis, diagnosis, and treatment.

Chinese medical journal
2025

Hospitalized generalized pustular psoriasis vs. acute generalized exanthematous pustulosis: A comprehensive analysis of clinical manifestations and treatment outcomes.

Chinese medical journal
2025

Pustular reaction in adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies.

Frontiers in immunology
2025

Clinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study.

Annales de dermatologie et de venereologie
2025

Economic burden and cost drivers of generalized pustular psoriasis: a systematic review.

Health economics review
2026

Real-world treatment patterns in patients with generalized pustular psoriasis: A US-based claims study.

Journal of the American Academy of Dermatology
2025

Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review.

American journal of clinical dermatology
2026

microRNA-223 Expression during Flares in Patients with Generalized Pustular Psoriasis Is Regulated by Spesolimab Treatment.

The Journal of investigative dermatology
2025

Hydroxychloroquine-Induced Generalized Pustular Psoriasis Successfully Treated With Secukinumab: A Case Report.

The Journal of dermatology
2025

Health-related quality of life of adults with generalized pustular psoriasis in Malaysia: a cross-sectional study.

Orphanet journal of rare diseases
2026

Pediatric Generalized Pustular Psoriasis Responsive to Colchicine: A Cost-Effective Alternative to Biologics.

Pediatric dermatology
2025

Autoimmune Hemolytic Anemia in a Patient with Generalized Pustular Psoriasis Treated with Brodalumab: A Case Report.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
2025

Successful Treatment of Pediatric Generalized Pustular Psoriasis With Adalimumab: Case Report and Literature Review.

International journal of rheumatic diseases
2025

Outcomes of spesolimab treatment of generalized pustular psoriasis and psoriasis with pustules for 12 weeks: A prospective cohort study from China.

Journal of the American Academy of Dermatology
2025

Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene.

Cell genomics
2025

Spesolimab Treatment in GPP: Impact of IL-36RN Mutations and Concomitant Plaque Psoriasis.

Clinical, cosmetic and investigational dermatology
2025

Generalized Pustular Psoriasis as a Systemic Inflammatory Disease: Experience With 38 Japanese Cases Over 15 Years at a Single Institution.

Cureus
2026

Disease Modification of Pustular Psoriasis by Secukinumab: A 20-Year Follow-Up of Von Zumbusch-Type Generalized Pustular Psoriasis With Evolution Into Annular Pustular Psoriasis-A Case Report.

The Kaohsiung journal of medical sciences
2025

Drug-Induced Generalized Pustular Psoriasis: A Systematic Review.

Journal of cutaneous medicine and surgery
2025

A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys.

Dermatology and therapy
2025

Classic Hodgkin lymphoma in a patient treated with ixekizumab for generalized pustular psoriasis.

European journal of dermatology : EJD
2026

Clinical and genetic characteristics of generalized pustular psoriasis: A retrospective study based on a registry database.

Chinese medical journal
2025

Decoding Non-Coding RNA Regulators in DITRA: From Genomic Insights to Potential Biomarkers and Therapeutic Targets.

Genes
2025

Healthcare resource utilization and economic burden in generalized pustular psoriasis (GPP) among U.S. adults: A large claims database analysis.

Journal of the American Academy of Dermatology
2025

Bilateral Multiple Chalazia After Adalimumab Therapy for Uveitis Associated With Generalized Pustular Psoriasis: A Case Report.

Cureus
2025

Achieving Therapeutic Success with Spesolimab: Two Cases of Drug-Induced Generalized Pustular Psoriasis Initially Mimicking Acute Generalized Exanthematous Pustulosis.

Journal of inflammation research
2025

Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany - Methodology and Outcomes of Claims Data Analysis.

Psoriasis (Auckland, N.Z.)
2025

Concurrent superficial epidermolytic ichthyosis and generalized pustular psoriasis - Report of a case, review of the literature, and a proposed pathophysiologic link.

JAAD case reports
2025

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares.

The Journal of clinical investigation
2025

Generalized pustular psoriasis in a patient with asthma following dupilumab and tezepelumab therapy.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2025

Dermal adipogenesis protects against neutrophilic skin inflammation during psoriasis pathogenesis.

Cellular &amp; molecular immunology
2025

Successful Treatment of Adalimumab-Induced Pustular Psoriasis With Guselkumab in a Patient With Hidradenitis Suppurativa.

Cureus
2025

Targeting IL-23 in Generalized Pustular Psoriasis: Clinical Success With Guselkumab in an Elderly Patient With Comorbidities.

International journal of dermatology
2025

Generalized Pustular Psoriasis.

The New England journal of medicine
2025

Neutrophils in generalized pustular psoriasis: Key players in disease progression.

Chinese medical journal
2026

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab.

Dermatology reports
2025

Unraveling Psoriasis Flare-up and Dengue Infection.

Journal of psoriasis and psoriatic arthritis
2025

All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis.

Journal of psoriasis and psoriatic arthritis
2025

Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience.

Clinical and experimental dermatology
2025

Spesolimab in generalized pustular psoriasis complicated by acrodermatitis continua of Hallopeau: a case report and mechanistic insights.

Frontiers in immunology
2025

Paradoxical development of prurigo nodularis during ixekizumab therapy in a patient with generalized pustular psoriasis and psoriatic arthritis.

European journal of dermatology : EJD
2025

Generalized Pustular Psoriasis During Early Pregnancy Successfully Treated with Spesolimab: A Case Report.

International medical case reports journal
2025

Treatment Status for Generalized Pustular Psoriasis in Japanese Patients: A Retrospective Chart Review.

Dermatology and therapy
2025

Generalized Pustular Psoriasis with Cushing's Syndrome: A Case of Effective Spesolimab Treatment.

Biologics : targets &amp; therapy
2025

Annular pustular psoriasis: A heterogeneous subtype of generalized pustular psoriasis.

Chinese medical journal
2025

Update on Generalized Pustular Psoriasis.

Acta medica portuguesa
2025

Generalized Pustular Psoriasis-Like Eruption Triggered by a G-CSF-Producing Lung Adenocarcinoma.

The Journal of dermatology
2025

Generalized pustular psoriasis (von Zumbusch) flares successfully treated with Spesolimab. Report of two cases and review of the literature.

Anais brasileiros de dermatologia
2025

Immunoproteomic Response to IL-17A Blockade in a Patient With Generalized Pustular Psoriasis: New Insights From Plasma Olink Profiling.

The Journal of dermatology
2025

Medications Associated With Generalized Pustular Psoriasis Flares: A Retrospective Pharmacovigilance Study.

Journal of cutaneous medicine and surgery
2025

Epidemiology and admission outcomes of generalized pustular psoriasis: a report from the national inpatient sample.

Archives of dermatological research
2025

Successful treatment of generalized pustular psoriasis with chronic hepatitis B using spesolimab: A case report.

Medicine
2025

Effective Spesolimab Treatment for Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report.

Cureus
2025

A Case of Parkinsonism Manifested by Exacerbation of Generalized Pustular Psoriasis.

The Journal of dermatology
2026

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares: An Observational, Retrospective, and Multicenter Study of Effectiveness and Safety in Real-World Clinical Practice.

International journal of dermatology
2025

Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab.

Pediatric dermatology
2025

Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
2025

Journey of Patients with Psoriasis in an Italian Tertiary Centre, an 11-year Retrospective Analysis.

Acta dermato-venereologica
2025

Successful Management of Refractory Generalized Pustular Psoriasis With Spesolimab.

American journal of therapeutics
2025

Safety and effectiveness of secukinumab in Japanese patients with generalized pustular psoriasis: A post-marketing surveillance.

The Journal of dermatology
2025

Epidemiological, Genetic, Clinical, and Treatment Differences of Generalized Pustular Psoriasis and Acrodermatitis Continua of Hallopeau Across Ethnicities: A Systematic Review.

American journal of clinical dermatology
2025

Generalized Pustular Psoriasis Brazilian Experts Survey: Challenges in Disease Management.

Dermatology and therapy
2025

Acrodermatitis Continua of Hallopeau and Generalised Pustular Psoriasis: Case Reports of Two Different Manifestations of IL36RN Mutation in Siblings.

Psoriasis (Auckland, N.Z.)
2025

Efficacy and safety of spesolimab in the treatment of generalized pustular psoriasis in elderly patients.

Annales de dermatologie et de venereologie
2025

Generalized Pustular Psoriasis with Breast Cancer Successfully Treated with Spesolimab Causing Neutrophilia: A Case Report.

Acta dermato-venereologica
2025

Abrocitinib Treatment for Localized Type of Generalized Pustular Psoriasis: A Case Report.

Clinical, cosmetic and investigational dermatology
2025

Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching-A Japanese e-Delphi Survey.

Dermatology and therapy
2025

Real-Life Analysis of Therapeutic Management and Its Correlation with the Dermatology Life Quality Index Score in 108 Patients with Pustular Psoriasis: An Italian Monocenter Study.

Dermatology practical &amp; conceptual
2025

Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report.

The Journal of dermatological treatment
2025

Just the facts: diagnosis and management of generalized pustular psoriasis.

CJEM
2025

Proteomic Profiling and Clinical Insights: The Role of MMP9 in Differentiating Psoriasis Vulgaris from Generalized Pustular Psoriasis.

Journal of inflammation research
2025

Current status of generalized pustular psoriasis: Findings from a multicenter hospital-based survey of 127 Chinese patients.

Chinese medical journal
2025

Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post-marketing surveillance.

The Journal of dermatology
2025

From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

The Journal of clinical and aesthetic dermatology
2025

Exploring the Significance of Eosinophil Infiltration in Diagnosis of Psoriasis: A Cross-sectional Analysis.

Iranian journal of pathology
2025

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.

Journal of the American Academy of Dermatology
2025

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares.

Journal of drugs in dermatology : JDD
2025

Case report: Efficacy of tofacitinib in the treatment of generalized pustular psoriasis.

Frontiers in medicine
2025

Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2025

Quality of life of patients with pustular psoriasis is inferior to that of patients with plaque psoriasis in Japan: A multicenter study with questionnaires, the short Form-36, and other patient-reported outcomes.

The Journal of dermatology
2025

Characteristics and Outcomes of Generalized Pustular Psoriasis Patients Managed Through Inpatient Asynchronous Teledermatology: A Retrospective Study.

Telemedicine reports
2025

IL-36-driven pustulosis: Transcriptomic signatures match between generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis (AGEP).

The Journal of allergy and clinical immunology
2025

Efficacy of granulocyte and monocyte adsorptive apheresis on skin and joint manifestations of palmoplantar pustulosis with pustulotic arthro-osteitis: A multicentric, prospective, observational study.

The Journal of dermatology
2025

Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis.

Italian journal of pediatrics
2025

Real-world clinical characteristics and treatment patterns of generalized pustular psoriasis flares.

Journal of the American Academy of Dermatology
2025

Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis.

Expert opinion on biological therapy
2025

Generalized pustular psoriasis: a multicentric study on patient characteristics and clinical burden.

Orphanet journal of rare diseases
2024

Analysis of the German Compassionate Use Program on spesolimab in patients with generalized pustular psoriasis: evidence outside of clinical trials.

European journal of dermatology : EJD
2025

Effectiveness and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Single-centre Retrospective Study.

Acta dermato-venereologica
2025

Crusted Scabies in a Patient being Treated with Spesolimab for Generalized Pustular Psoriasis.

Acta dermato-venereologica
2025

Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion.

Journal of psoriasis and psoriatic arthritis
2025

Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis.

Italian journal of dermatology and venereology
2025

Healthcare Resource Utilization Among Patients With Generalized Pustular Psoriasis: The Impact of Flares and Disease Severity.

Journal of psoriasis and psoriatic arthritis
2025

Global Delphi consensus on treatment goals for generalized pustular psoriasis.

The British journal of dermatology
2025

Comments on Consensus for Generalized Pustular Psoriasis-Reply.

JAMA dermatology
2025

Comments on Consensus for Generalized Pustular Psoriasis.

JAMA dermatology
2025

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab.

Clinical, cosmetic and investigational dermatology
2025

Acute Generalized Exanthematous Pustulosis Induced by Hyaluronic Acid Knee Injection: A Case Report.

Journal of emergency nursing
2024

Eruption of Generalized Pustular Psoriasis Following Initiation of Adalimumab for Hidradenitis Suppurativa: A Case Report.

Cureus
2025

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study.

The Journal of dermatological treatment
2025

Recibokibart, an anti-IL-36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial.

Journal of the European Academy of Dermatology and Venereology : JEADV
2025

Rapid improvement in a recurrent generalized pustular psoriasis patient ineffective to Ixekizumab following Spesolimab therapy.

Anais brasileiros de dermatologia
2025

Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics.

Trends in immunology
2024

Etanercept: A viable treatment option for young children with generalized pustular psoriasis.

Pediatric investigation
2024

Efficacy of secukinumab in Takayasu arteritis with myocardial infarction complicated with generalized pustular psoriasis: A case report.

Medicine
2025

Updated genetic background of generalized pustular psoriasis as an autoinflammatory keratinization disease.

The Journal of dermatology
2024

Effectiveness and safety of spesolimab in treating generalized pustular psoriasis: A comparative analysis of randomized controlled trials.

Indian journal of pharmacology
2024

Unveiling the skin microbial guardians and assailants in psoriasis subtypes: a Mendelian randomization study.

Archives of dermatological research
2025

Real-World Experience of Spesolimab for Generalized Pustular Psoriasis Flares in Adult Patients: A Multicenter Retrospective Study.

American journal of clinical dermatology
2024

Characteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis Group.

Dermatology and therapy
2025

Innovations in Psoriasis.

Dermatologic clinics
2024

Exploring the Chronic Nature of Generalized Pustular Psoriasis [Podcast].

Clinical, cosmetic and investigational dermatology
2024

Successful Treatment of Pediatric Generalized Pustular Psoriasis (GPP) with Spesolimab: 5 Case Reports and Evaluations of Circulating IL-36 Levels.

Journal of inflammation research
2024

Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis.

Frontiers in immunology
2024

Long-term remission and normal pregnancy with successful delivery in a patient with generalized pustular psoriasis after spesolimab.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2024

Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis.

The Journal of dermatology
2024

IL36RN Mutations and Correlated Characteristics in Generalized Pustular Psoriasis Patients in Can Tho City, Vietnam: A Cross-Sectional Study.

Dermatology (Basel, Switzerland)
2024

Spesolimab, the first-in-class anti-IL-36R antibody: From bench to clinic.

The Journal of dermatology
2024

Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis.

Journal of inflammation research
2025

Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab.

The Journal of dermatology
2023

Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis.

Journal of psoriasis and psoriatic arthritis
2024

[Translated article] Elderly-Onset Generalized Pustular Psoriasis in the Elderly: A 5-Case Series.

Actas dermo-sifiliograficas
2025

Considerations for defining and diagnosing generalized pustular psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV
2024

Plaque psoriasis, generalized pustular psoriasis, palmoplantar pustulosis, and acrodermatitis continua of Hallopeau successfully treated with bimekizumab: a promising therapeutic approach.

European journal of dermatology : EJD
Ver todos os 846 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Psoríase pustular generalizada.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Psoríase pustular generalizada

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. [Role and clinical significance of PD-L1+ neutrophils in generalized pustular psoriasis].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology· 2026· PMID 41620967mais citado
  2. Disease Modification of Pustular Psoriasis by Secukinumab: A 20-Year Follow-Up of Von Zumbusch-Type Generalized Pustular Psoriasis With Evolution Into Annular Pustular Psoriasis-A Case Report.
    The Kaohsiung journal of medical sciences· 2026· PMID 40798863mais citado
  3. Repeated Episodes of GPP Induced by Respiratory Infections Are Mediated by Loss-of-Function IFIH1.
    Immunity, inflammation and disease· 2026· PMID 41847945mais citado
  4. Complications and Laboratory Test Findings Among Patients With Generalized Pustular Psoriasis: A Retrospective Chart Review Study.
    Experimental dermatology· 2026· PMID 41840359mais citado
  5. Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies.
    Cureus· 2026· PMID 41835689mais citado
  6. Unusual Presentation of Pustular Psoriasis on the Face: A Case Report.
    Cureus· 2026· PMID 41994815recente
  7. Juvenile Generalized Pustular Psoriasis: Management in Children-A Case Series.
    Clin Case Rep· 2026· PMID 41982855recente
  8. Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.
    Health Sci Rep· 2026· PMID 41953903recente
  9. Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP-GPP Overlap.
    Psoriasis (Auckl)· 2026· PMID 41940178recente
  10. The IL-36 Cytokine Rheostat: Hierarchical Regulation of Epithelial-Immune Crosstalk and Precision Therapy in Psoriatic and Related Dermatoses.
    Clin Cosmet Investig Dermatol· 2026· PMID 41924293recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:247353(Orphanet)
  2. MONDO:0100491(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q5532501(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Psoríase pustular generalizada
Compêndio · Raras BR

Psoríase pustular generalizada

ORPHA:247353 · MONDO:0100491
Prevalência
1-9 / 1 000 000
Herança
Autosomal recessive, Not applicable
CID-10
L40.1 · Psoríase pustulosa generalizada
CID-11
Ensaios
12 ativos
Início
Adult
Prevalência
0.18 (France)
MedGen
UMLS
C0343055
Repurposing
23 candidatos
acitretinretinoid receptor agonist
anthralinDNA synthesis inhibitor
apremilastphosphodiesterase inhibitor
+17 outros
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades